In December 2017 IONIS announced their phase one clinical trial for a Huntingtin Lowering or ‘gene silencing treatment’ had produced promising results.
For a reminder follow the link below.
They also announced that pharmaceutical company Roche purchased the licence to continue to develop this potential treatment for HD.
Last year, Roche announced that the phase three trial would commence early in 2019 and today they have revealed the UK sites that will participate. These are:
Aberdeen – Aberdeen Royal Infirmary
Birmingham – Birmingham and Solihull Mental Health Foundation Trust
Cambridge – Cambridge Centre for Brain Repair
Cardiff – University Hospital of Wales
Glasgow – Queen Elizabeth University Hospital Glasgow
Leeds – Leeds General Infirmary
London – National Hospital for Neurology and Neurosurgery
Manchester – Central Manchester University Hospitals NHS Foundation Trust
Oxford – John Radcliffe Hospital
Sheffield – Sheffield Children’s NHS Trust
Southampton – University Hospital Southampton NHS Foundation Trust
We are incredibly excited that there will be two Scottish sites: Aberdeen and Glasgow and our congratulations go to Professor Zosia Miedzybrodzka and Dr Stuart Ritchie who are the Principal Investigators and their teams.
Although the Aberdeen and Glasgow site will begin recruitment soon, they are not open yet and the majority of people recruited will be drawn from those already participating in ENROLL HD.
If you would like more information about the study you can contact the Roche UK Medical Information team for more information on: 0800 3281629 or email@example.com.
You can read more about the trial here ClinicalTrials.gov
If you would like a refresher on how this treatment works, you can view this excellent article over at HD Buzz https://en.hdbuzz.net/265.